The content on this site is intended for healthcare professionals only
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression
Venetoclax plus rituximab for patients with relapsed / refractory CLL
Daratumumab for patients with multiple myeloma
Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma
Multiple myeloma analysis from ASH 2017
Multiple myeloma highlights from ASH 2017
ASH 2017: Immunotherapy for multiple myeloma
Edoxaban versus dalteparin for venous thromboembolism associated with cancer
Lenalidomide with rituximab for mantle cell lymphoma
Combination chemotherapy for multiple myeloma
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma
Gilteritinib combination with induction and consolidation chemo in newly diagnosed AML
REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies
Results of the AML 12 trial
Added ibrutinib in first-line CLL treatment
T cell therapy for ALL
Immunosuppressive therapy in myelodysplastic syndrome
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma
Hypomethylating agents for relapsed and refractory acute myeloid leukaemia
Epidemiology data for acute myeloid leukaemia and the ALESE study
Combination of steroids with ponatinib as frontline therapy for acute lymphoblastic leukaemia
Shortening the time to manufacture CAR T-cells
ASPIRE update: Carfilzomib triplet for relapsed / refractory myeloma
Early platelet drop in myelodysplastic syndrome highlights prognostic classifier
Six-month follow up of CTL019 for diffuse large B-cell lymphoma
New treatment strategies for multiple myeloma
Anti-BCMA CAR T cell therapy for multiple myeloma
Axicabtagene ciloleucel for patients with non-hodgkin lymphoma
Data from the CLARITY trial of ibrutinib plus venetoclax
Mogamulizumab for cutaneous T- cell lymphoma
Phase 1 study of Blu-285 in advanced systemic mastocytosis
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
New treatments for acute myeloid leukaemia
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma
Long term follow up on the ZUMA-1 trial for nHL
BLU-285 for advanced systemic mastocytosis
Mogamulizumab demonstrates significant improvement in progression free survival for CTCL
Autoimmune and infectious diseases among diffuse large B-cell lymphoma survivors
Autologous haematopoietic cell transplant for mantle cell lymphoma
Dexamethasone and the UKALL 2011 trial
